TL;DR
This study investigated two common approaches to managing anticoagulation in pregnant individuals at high risk for venous thromboembolism (VTE): continuing enoxaparin until delivery or switching to heparin. The findings suggest that continuing enoxaparin is non-inferior to switching to heparin, showing no significant differences in maternal or neonatal outcomes, including blood loss and the ability to receive neuraxial anesthesia.
What Problem Does This Paper Address?
Pregnancy naturally increases a woman's risk of blood clots (venous thromboembolism or VTE) due to changes in coagulation factors. For those requiring anticoagulation to prevent or treat VTE, managing their medication around labor and delivery presents a clinical challenge. Two main strategies exist: continuing enoxaparin (a low molecular weight heparin) until a scheduled induction, or switching to unfractionated heparin (UFH) closer to the due date, anticipating spontaneous labor. UFH has a shorter half-life, making it easier to reverse in emergencies, but it has less predictable pharmacokinetics and requires more frequent dosing. Enoxaparin is more predictable but its longer half-life can complicate management if labor starts unexpectedly, potentially delaying neuraxial anesthesia (like epidurals) due to bleeding risks. There's a lack of strong evidence to guide clinicians on which approach is safer and more effective, leading to practice variations. This paper aims to compare the obstetrical and neonatal outcomes of these two common practices.
Methods
The researchers conducted a retrospective review of 194 live singleton deliveries from 179 patients at a single tertiary referral center between January 2017 and May 2022. Patients were categorized into two groups based on their anticoagulation management: those who continued enoxaparin until delivery and those who transitioned to heparin. To account for potential confounding factors, a Bayesian logistic regression model was employed. This statistical approach allowed them to control for variables such as age, BMI, number of previous deliveries, dosing regimens (prophylactic, intermediate, or therapeutic), gestational age at delivery, labor spontaneity, mode of delivery, and concurrent sterilization. For comparing population statistics, a non-parametric Welch test was used.
Datasets
The study utilized a dataset of 194 patient charts from a single tertiary referral center, collected between January 2017 and May 2022. This dataset was derived from patients admitted to the labor and delivery unit who were prescribed antenatal anticoagulation.
Key Insights and Ideas
- Enoxaparin's Predictability is Manageable: Despite concerns about enoxaparin's longer half-life and unpredictable labor onset, the study found that continuing it until delivery did not lead to worse outcomes compared to switching to heparin. This suggests that the clinical impact of its longer half-life might be mitigated by the ability to hold a dose when labor begins.
- Neuraxial Anesthesia Availability is Unaffected: A key concern with enoxaparin is its potential to delay neuraxial anesthesia. However, this study found no statistically significant difference in the ability of patients to receive neuraxial anesthesia between the two groups, indicating that this practice doesn't necessarily compromise pain management options.
- Clinical Significance vs. Statistical Significance: The paper highlights that while there might be theoretical differences in drug pharmacokinetics, the clinical outcomes observed were similar. This implies that for many patients, the choice of anticoagulation strategy may not have a significant impact on their delivery experience or their baby's health.
- Spontaneous Labor is Often Prodromal: The findings suggest that spontaneous labor is often sufficiently "prodromal" (i.e., it develops gradually) to allow for a dose of enoxaparin to be held prior to delivery, thereby reducing active metabolites and minimizing bleeding risk.
Key Results
- There were no statistically significant differences in obstetrical or neonatal outcomes between the enoxaparin and heparin groups.
- The primary outcome, estimated blood loss at delivery, was similar: 497 mL (±378) for the heparin group versus 491 mL (±311) for the enoxaparin group.
- Ability to receive neuraxial anesthesia was also comparable, with 71% of patients in both groups able to receive it.
- Secondary outcomes, including birthweight, 1- and 5-minute APGAR scores, and NICU admissions, showed no significant differences.
- There were no readmissions for bleeding, hematoma, wound infection, or reoperation in either group.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The study had a relatively small sample size, particularly for patients on intermediate and therapeutic dosing of anticoagulants. This could limit the power to detect statistically significant differences in bleeding outcomes.
- Retrospective Design: As a retrospective review from a single center, the findings may be subject to biases and might not be generalizable to other institutions with different practices.
- Blood Loss Measurement Inconsistency: Blood loss for vaginal deliveries was estimated, while for cesarean deliveries it was measured quantitatively, introducing a potential inconsistency.
- Non-Randomized Collection: Patient collection was non-random, which can affect internal validity.
- Medication Adherence Assumption: The study assumed medication adherence based on home reconciliation, which may not always be accurate.
Future directions suggested include:
- Expanding to Multiple Centers: Conducting similar studies across multiple labor and delivery units to increase external validity.
- Characterizing Last Dose Timing: Future research should focus on characterizing the timing of the last anticoagulant dose prior to delivery to better understand its impact.
- Prospective Noninferiority Trials: Prospective trials are needed to make practice-changing recommendations.
- Pharmacokinetic Studies: Further pharmacokinetic studies could help validate heparin-monitoring laboratory values in pregnant patients.
Summary updated